ethyl 2-(4-(trifluoromethyl)phenyl)oxazole-4-carboxylate | 1357944-10-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: ethyl 2-(4-(trifluoromethyl)phenyl)oxazole-4-carboxylate
• 英文别名: 2-[4-(Trifluoromethyl)phenyl]oxazole-4-carboxylic acid ethyl ester；ethyl 2-[4-(trifluoromethyl)phenyl]-1,3-oxazole-4-carboxylate
• CAS: 1357944-10-5
• 化学式: C₁₃H₁₀F₃NO₃
• 分子量: 285.223
• InChiKey: ZLISLIFQQVPJFK-UHFFFAOYSA-N

物化性质

• 沸点：
  340.9±52.0 °C(Predicted)
• 密度：
  1.304±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  52.3
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  ethyl 2-(4-(trifluoromethyl)phenyl)oxazole-4-carboxylate 在 palladium on activated carbon 、 氢气 、 palladium diacetate 、 potassium carbonate 、 caesium carbonate 、 三苯基膦 作用下， 以 甲醇 、 乙二醇二甲醚 、 N,N-二甲基甲酰胺 为溶剂， 90.0~140.0 ℃ 、344.75 kPa 条件下， 反应 16.0h， 生成 2-(4-(trifluoromethyl)phenyl)oxazolo[4,5-c]quinolin-4(5H)-one
  参考文献：
  名称：

  恶唑并[4,5-c]-喹啉酮类似物作为新型白细胞介素33抑​​制剂的合理设计、合成和评价

  摘要：

  的恶唑并[4,5-C] -喹啉酮类似物7  Ç是白细胞介素33的第一小分子抑制剂，其结合至IL-33和ST2的在2D NMR研究的接口和白细胞介素的强抑制证明-6 在人类肥大细胞中产生。

  DOI：

  10.1002/asia.202100896
• 作为产物：
  描述：

  (4-Trifluoromethyl-benzoylamino)-acetic acid ethyl ester 在 18-冠醚-6 、 碘 、 sodium hydride 、 三乙胺 、 三苯基膦 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 6.0h， 生成 ethyl 2-(4-(trifluoromethyl)phenyl)oxazole-4-carboxylate
  参考文献：
  名称：

  使用C-甲酰化策略从常见的无环前体合成咪唑，恶唑，噻唑和2,5-二羧酸吡嗪二乙酯的取代酯

  摘要：

  报道了一种通过甘氨酸乙酯盐酸盐的C-甲酰化反应合成咪唑，恶唑，噻唑和吡嗪-2,5-二羧酸二乙酯的取代酯的新颖合成途径。该方法简单，稳健，并且可以在一个或两个步骤中从常见的无环前体中很好地获得不同杂环酯的收率，并且适合大规模合成。

  DOI：

  10.1016/j.tetlet.2014.03.039

文献信息

• Radical C–H Arylation of Oxazoles with Aryl Iodides: dppf as an Electron-Transfer Mediator for Cs₂CO₃
  作者：Zhengwei Guo、Man Li、Xue-Qing Mou、Gang He、Xiao-Song Xue、Gong Chen

  DOI：10.1021/acs.orglett.8b00530

  日期：2018.3.16

  A radical C–H arylation reaction of oxazoles with (hetero)aryl iodides using Cs2CO3 as base/electron donor and 1,1′-bis(diphenylphosphino) ferrocene (dppf) as a catalytic SET mediator is reported. The overall reaction likely follows the general base-promoted homolytic aromatic substitution mechanism through a radical-chain pathway. DFT calculations suggest that dppf forms a complex with CsCO3–, enhancing

  报道了使用Cs 2 CO 3作为碱/电子给体和1,1'-双（二苯基膦基）二茂铁（dppf）作为催化SET介体，恶唑与（杂）芳基碘化物的自由基CH芳基化反应。整个反应可能通过自由基链途径遵循一般的碱促进的均质芳族取代机理。DFT计算表明，dppf与CsCO 3 –形成络合物，增强了SET还原能力，可从ArI生成芳基。
• NOVEL QUINOLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALLERGIC DISEASES SUCH AS ASTHMA OR ATOPIC DERMATITIS INCLUDING THE QUINOLINONE DERIVATIVE AS ACTIVE INGREDIENT
  申请人：Korea University Research and Business Foundation, Sejong Campus

  公开号：US20200140457A1

  公开（公告）日：2020-05-07

  The present invention relates to anovel quinolinone derivative compound that regulates intracellular signal transduction mediated by TSLP and IL-33 to exhibit efficacy in preventing or treating allergic diseases such as asthma or atopic dermatitis. The quinolinone derivative compound of the present invention can effectively suppress inflammatory responses of allergic diseases such as asthma or atopic dermatitis. The present invention also relates to a pharmaceutical composition including the quinolinone derivative compound. The pharmaceutical composition of the present invention can be used to fundamentally prevent or treat various allergic and asthmatic diseases.

  本发明涉及一种新型喹诺酮衍生物化合物，通过调节由TSLP和IL-33介导的细胞内信号传导，以在预防或治疗哮喘或特应性皮炎等过敏疾病中发挥功效。本发明的喹诺酮衍生物化合物可以有效抑制哮喘或特应性皮炎等过敏疾病的炎症反应。本发明还涉及包括喹诺酮衍生物化合物的药物组合物。本发明的药物组合物可用于根本预防或治疗各种过敏和哮喘疾病。
• Pd-catalyzed desulfitative arylation for the synthesis of 2,5-diarylated oxazole-4-carboxylates using dioxygen as the terminal oxidant
  作者：Xiaodong Tang、Kai Yang、Liying Zeng、Qiang Liu、Huoji Chen

  DOI：10.1039/c7ob01912b

  日期：——

  A novel palladium-catalyzed approach for constructing 2,5-diarylated oxazole-4-carboxylates using sodium arylsulfinates as the aryl source has been demonstrated.

  一种新颖的钯催化方法已被证明可用于利用亚砜酸钠作为芳基来源构建2,5-二芳基氧唑-4-羧酸酯。
• NOVEL QUINOLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALLERGIC DISEASE SUCH AS ASTHMA OR ATOPY COMPRISING SAME AS ACTIVE INGREDIENT
  申请人：Korea University Research and Business Foundation, Sejong Campus

  公开号：EP3567044A1

  公开（公告）日：2019-11-13

  The present invention relates to a novel quinolinone derivative compound that regulates intracellular signal transduction mediated by TSLP and IL-33 to exhibit efficacy in preventing or treating allergic diseases such as asthma or atopic dermatitis. The quinolinone derivative compound of the present invention can effectively suppress inflammatory responses of allergic diseases such as asthma or atopic dermatitis. The present invention also relates to a pharmaceutical composition including the quinolinone derivative compound. The pharmaceutical composition of the present invention can be used to fundamentally prevent or treat various allergic and asthmatic diseases.

  本发明涉及一种新型喹啉酮衍生物化合物，该化合物可调节由 TSLP 和 IL-33 介导的细胞内信号转导，从而在预防或治疗哮喘或特应性皮炎等过敏性疾病方面发挥功效。 本发明的喹啉酮衍生物化合物可有效抑制哮喘或特应性皮炎等过敏性疾病的炎症反应。 本发明还涉及一种包括喹啉酮衍生物化合物的药物组合物。 本发明的药物组合物可用于从根本上预防或治疗各种过敏性疾病和哮喘疾病。
• Quinolinone derivative and pharmaceutical composition for preventing or treating allergic diseases such as asthma or atopic dermatitis including the quinolinone derivative as active ingredient
  申请人：Azcuris Co., Ltd.

  公开号：US11168094B2

  公开（公告）日：2021-11-09

  The present invention relates to a novel quinolinone derivative compound that regulates intracellular signal transduction mediated by TSLP and IL-33 to exhibit efficacy in preventing or treating allergic diseases such as asthma or atopic dermatitis. The quinolinone derivative compound of the present invention can effectively suppress inflammatory responses of allergic diseases such as asthma or atopic dermatitis. The present invention also relates to a pharmaceutical composition including the quinolinone derivative compound. The pharmaceutical composition of the present invention can be used to fundamentally prevent or treat various allergic and asthmatic diseases.

  本发明涉及一种新型喹啉酮衍生物化合物，该化合物可调节由 TSLP 和 IL-33 介导的细胞内信号转导，从而在预防或治疗哮喘或特应性皮炎等过敏性疾病方面发挥功效。本发明的喹啉酮衍生物化合物可有效抑制哮喘或特应性皮炎等过敏性疾病的炎症反应。本发明还涉及一种包括喹啉酮衍生物化合物的药物组合物。本发明的药物组合物可用于从根本上预防或治疗各种过敏性疾病和哮喘疾病。